Best Pre-Workout Powder of 2022, According to Dietician

Via Peters

Best Pre-Workout Powder of 2022

Next Post

Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer

In 2013, ado-trastuzumab emtansine (T-DM1; Kadcyla) gained FDA approval for the treatment of patients with HER2-positive metastatic breast cancer (MBC), making it the first antibody-drug conjugate (ADC) with an indication for a solid tumor. Since then, ADCs have become one of the fastest-growing classes of oncology drug therapy.1,2 In breast […]